322 results about "Kidney disease" patented technology

The invention relates to a nephrotic patient health management method and system based on a neural network prediction model, and the method comprises the steps: obtaining the multi-dimensional health data of a target nephrotic patient at each stage, constructing a time sequence feature matrix to extract the change trend of the whole course of disease, and dividing the course of disease into a disease alleviation stage and a disease deterioration stage; analyzing the health data of the two stages to obtain an improvement factor and a deterioration factor; outputting a renal function state prediction result by using a neural network prediction model fusing an attention mechanism and a knowledge graph, and generating an initial health management scheme by combining the result, a preset health management rule base and patient preferences; and optimizing the initial scheme based on the improvement factor, the deterioration factor and a reinforcement learning algorithm to obtain an optimized health management scheme. Complete-cycle closed-loop management of data acquisition, trend analysis, factor identification, prediction and early warning, scheme generation and dynamic optimization of nephropathy patients is realized, and the accuracy and individuation level of nephropathy health management are improved.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention relates to the technical field of combination of medical treatment and computers, and discloses a kidney disease risk prediction method and system based on machine learning and a storage medium, and the method comprises the steps: collecting basic data of historical patients, carrying out the preprocessing of the basic data, and adding a label to serve as first learning data; constructing a plurality of first prediction models based on machine learning, training the first prediction models by using the first learning data, obtaining first prediction data, and integrating the first prediction data to generate a first data set; adding the first data set into the first learning data to form second learning data; constructing a plurality of second prediction models, training the second prediction models by using the second learning data, and selecting a target prediction model from the second prediction data; the basic data of the new patient is obtained and input into the target prediction model, the target prediction model outputs the prediction value of the kidney disease risk of the new patient, and the kidney disease risk can be predicted more accurately.

The invention relates to the technical field of microorganisms, in particular to compound probiotics capable of degrading indole and preventing or relieving nephropathy and application of the compound probiotics. The compound probiotics comprise bifidobacterium animalis subsp. Lactis YYS-J9 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.28185 and bifidobacterium longum subsp. Longum YYS-BSM8 with the preservation number of CGMCC NO.28611. The invention further discloses a preparation method of the compound probiotics. Compared with the use of a single YYS-J9 strain or YYS-BSM8 strain, the two strains have synergistic effects after being compounded, the viable count is remarkably increased after mixed culture, the inhibition effect on pathogenic enterobacteria and the adhesion to intestinal cells are remarkably enhanced, the degradation capacity on indole and oxalic acid is higher, the proliferation and phagocytic activity of macrophages is remarkably improved, and the application range of the YYS-J9 strain and the YYS-BSM8 strain is widened. And when being applied to food, health-care products or medicines, the exopolysaccharide can be used for effectively preventing or improving nephropathy and kidney stone, regulating intestinal health and improving intestinal immunity.

The present disclosure provides engineered alpha klotho polypeptides and methods of their production and use. Soluble alpha klotho polypeptides disclosed herein comprise an alpha klotho moiety having one or more mutations for enhancing activity, production yield, and / or stability relative to human alpha klotho. The disclosure further provides pharmaceutical compositions comprising the engineered alpha klotho polypeptides, and methods of use of the engineered alpha klotho polypeptides in treatment methods, including treatment of age- related conditions and kidney disease. Also disclosed are nucleic acids encoding the engineered alpha klotho polypeptides, recombinant cells that express the engineered alpha klotho polypeptides, and methods of producing the engineered alpha klotho polypeptides.

The invention relates to thiophenyl derivatives and their use in the treatment and prophylaxis of diseases alleviated by APOL1 inhibition, such as an APOL1 mediated kidney disease, and to compositions containing said derivatives and processes for their preparation.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention discloses a pet prescription wet food with a long-acting fresh-keeping function and a preparation method of the pet prescription wet food, and relates to the technical field of preparation of pet food. Comprising 40-60% of a meat raw material, 5-15% of dietary fibers, 0.5-2% of a vitamin premix, 0.3-1.5% of a mineral pre-coagulated material, 0.1-2% of a probiotic compound, 0.05-0.2% of a natural antioxidant, and the balance of water, hydrolyzed chicken, the natural antioxidant and a compound additive. According to the preparation method, a staged gradient sterilization process is combined with three-layer composite packaging and low-temperature plasma treatment, the unopened shelf life is prolonged to 24 months, which is far better than that of a traditional process, and the activity of thermosensitive components is guaranteed by adopting a nano-liposome embedding technology and sodium alginate-chitosan embedded probiotics, so that the preparation method is simple and convenient to operate. The protein digestibility is improved to 92% through low-molecular hydrolyzed protein, and the requirements of pets with kidney diseases are met.

The invention relates to the technical field of medical care informatics, in particular to a nephropathy medication interaction risk screening system which comprises a data acquisition unit, an SOC chip processing and analysis unit, a risk early warning unit and a man-machine interaction and communication unit. Through multi-source data access, dynamic weight scheduling and Kalman filtering fusion correction, accurate and on-demand acquisition of nephropathy core indexes is realized, and real-time intelligent discrimination of personalized medication risks is realized by relying on knowledge base support, adaptive path adjustment and a safe atomization updating mechanism, so that the risk of the nephropathy is accurately determined. Therefore, the problems that traditional system data acquisition lacks specialized pertinence, risk assessment personalization is insufficient, and model updating is lagged are effectively solved, and the accuracy and timeliness of nephropathy medication interaction risk screening are remarkably improved.

The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor current and convert the sensor current generated by the continuous analyte sensor into digital signals, a processor configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.

The invention relates to the technical field of image recognition, and discloses an image feature recognition method and system applied to the early stage of kidney diseases. According to the method, the features in the original ultrasonic image are extracted in parallel, and the micro texture change and the macroscopic form information shown in the abnormal area can be captured respectively, so that the limitation of a traditional single-scale feature extraction method in coping with diffusive and weak-saliency image features is overcome; the local texture feature map and the global structure feature map are analyzed, quantization and positioning of weak texture changes are achieved, priori knowledge is converted into objective indexes, pixel-level fusion is carried out on a texture abnormal map and a region importance weight map, and through the knowledge-guided and data-driven deep fusion method, the deep fusion of the texture abnormal map and the region importance weight map is achieved. It is ensured that the finally recognized abnormal area is not only a statistical outlier but also conforms to importance distribution of an image structure, and high-precision automatic recognition of weak and diffuse features in the kidney medical image is facilitated.

The invention discloses a potential nephropathy prediction electronic nose system and method based on machine learning, and belongs to the technical field of medical detection. According to the system, ammonia concentration and temperature and humidity parameters in exhaled air of a human body are collected through a multi-mode sensor module, baseline calibration, flow velocity compensation and noise filtering are carried out in combination with a data preprocessing module, and a standardized characteristic matrix is generated. The machine learning prediction model adopts a Bayesian deep learning or integrated learning algorithm, inputs an ammonia concentration peak value, an integral area and temperature and humidity parameters, outputs a nephropathy risk probability and stage prediction, and quantifies key influence factors through an SHAP value (for example, a high-risk alarm is triggered when an ammonia concentration contribution degree is greater than or equal to 60%). The system is equipped with a real-time GUI interaction interface, dynamically displays a risk thermodynamic diagram and multi-dimensional data overlay analysis, and supports clinicians to feed back and correct. And the data iteration module realizes continuous optimization of the model through an encrypted cloud storage and incremental learning framework (Online SGD). A heterogeneous sensor array (such as a Fe2Mo3O8 / MoO2 (at) MoS2 composite material) and a dynamic temperature and humidity compensation technology are adopted, so that the detection stability is remarkably improved, and the clinical misdiagnosis rate is reduced. The system can be integrated in a portable device or a hospital system, is suitable for community screening, emergency triage and remote medical scenes, and has the advantages of noninvasive, high-precision and cross-mechanism collaborative diagnosis.

Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.

The present disclosure provides a method and an apparatus for predicting a progression trajectory from acute kidney injury (AKI) to a kidney disease. The method includes the following steps: receiving a first set of features of a particular acute kidney injury (AKI) patient; selecting a second set of features from the first set of features using a preset algorithm; and predicting, using a first machine-learning model, a progression trajectory of a kidney disease of the particular AKI patient based on the second set of features.

Provided herein are compounds that are useful in treating cancer, metabolic disease, cardiovascular disease, and kidney disease.

The invention relates to a construction method, an evaluation method and application of an inflammatory nephropathy animal model, and relates to the technical field of nephropathy animal model construction. The construction method comprises the steps that a CRIPSR / Cas9 system is adopted to shear a first targeting site on an Smu region of a mouse immune globulin gene, and a second targeting site on an Sgamma2c region of the mouse immune globulin gene is sheared, so that a base sequence between the first targeting site and the second targeting site is knocked out, and the inflammatory nephropathy animal model is obtained. The application comprises an application of the inflammatory nephropathy animal model constructed by the construction method in screening drugs for treating inflammatory nephropathy and an application in researching a molecular mechanism of occurrence and development of inflammatory nephropathy.

The invention discloses a method for constructing a pressed butterfly mycin glycoside gene engineering strain by using glycosyl transferase and application of the pressed butterfly mycin glycoside gene engineering strain. A strong promoter kasOp * is introduced to the upstream of a glucoside transferase gene pie28 of Streptomyces psammoticus SCSIO NS126, the nucleotide sequence of the strong promoter kasOp * is as shown in SEQ ID NO. 1, and the nucleotide sequence of the glucoside transferase pie28 is as shown in SEQ ID NO. 2. The invention also discloses a preparation method of the Streptomyces psammoticus SCSIO NS126, and the preparation method of the Streptomyces psammoticus SCSIO NS126 comprises the following steps of: introducing the strong promoter kasOp * into the upstream of the glucoside transferase gene pie28. The streptomyces gene engineering strain Streptomyces sp. SK-kas28 constructed by the invention can efficiently express the chalcone glycoside, is widely applied to fermentation production of the chalcone glycoside, and is used for research and development of new drugs for treating kidney diseases and the like.

The invention relates to the technical field of health assessment, in particular to a remote monitoring method and system for kidney disease patients. Similarity is obtained according to trend items and season items of adjacent time sequence segments in the sign monitoring time sequence; obtaining a sign monitoring segment according to the similarity of all adjacent time sequence segments; clustering the physical sign monitoring sections of the patient, and obtaining an abnormal disturbance difference value according to the difference characteristics of the residual items corresponding to the physical sign monitoring sections in the physical sign state cluster; obtaining an abnormal characterization value according to the residual item corresponding to the physical sign monitoring section in the physical sign state cluster, the abnormal disturbance difference value and the physical sign monitoring section; and obtaining a comprehensive abnormal index according to the abnormal representation values of all the physical sign state clusters of the patient. According to the body difference characteristics of the patient and other patients in the patient cluster, the abnormal early warning index is obtained by integrating the difference characteristics of the abnormal indexes and the difference characteristics of the sign monitoring time sequence, and early warning is carried out, so that the accuracy of remotely monitoring the state of the patient is improved.

The invention discloses a preparation method of a medicine for treating kidney diseases. The medicine comprises the following raw materials in parts by weight: 10-15 parts of astragalus membranaceus, 8-12 parts of salvia miltiorrhiza, 6-10 parts of angelica sinensis, 3-5 parts of cinnamon, 4-8 parts of safflower carthamus, 6-10 parts of bamboo leaves, 8-12 parts of artemisia apiacea, 4-6 parts of junci medulla, 6-10 parts of sculellaria barbata, 6-20 parts of pyrrosia lingua, 5-10 parts of honeysuckle, 6-12 parts of fructus forsythiae, 8-15 parts of poria cocos, 4-6 parts of liquorice, 4-6 parts of radix angelicae pubescentis, 4-6 parts of radix ginseng rubra, 4-6 parts of decaisnea insignis and 4-6 parts of Qianju. , 4-6 parts of Chinese yam, 4-6 parts of turtle shell and 4-6 parts of burdock; the traditional Chinese medicine composition has the beneficial effects that the medicine formula is more optimized, various Chinese herbal medicine raw materials with the effects of clearing away heat and toxic materials, promoting blood circulation to remove blood stasis and the like are selected, and the curative effect and safety of the medicine are improved through scientific compatibility; the preparation method is more perfect, and effective components in the Chinese herbal medicines are effectively extracted through the steps of crushing, decocting, concentrating, drying and the like.

Provided herein are compounds that are useful in treating cancer, metabolic disease, cardiovascular disease, and kidney disease.

The invention discloses a substituted aromatic heterocyclic compound containing a spiro skeleton as well as a preparation method and application thereof, and relates to the field of medicinal chemistry, in particular to the substituted aromatic heterocyclic compound containing the spiro skeleton or pharmaceutically acceptable salt of the substituted aromatic heterocyclic compound, a necessary composition containing the compounds and medical application of the substituted aromatic heterocyclic compound. The invention relates to an application of a monoacylglyceridase inhibitor, in particular to application of the monoacylglyceridase inhibitor as a monoacylglyceridase (MAGL) inhibitor in preparation of drugs for preventing and / or treating MAGL-related diseases. Comprise depression, schizophrenia, bi-directional disorder, dyskinesia, traumatic brain injury, neuroinflammation, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, anxiety disorder, pain, metabolic disorder, alcoholic fatty liver disease, non-alcoholic fatty liver disease, hepatic fibrosis, cholestasis, nephropathy and other related diseases.

This invention discloses the isolation, extraction, and novel application of a neutral, water-soluble polysaccharide from Sophora japonica extract. The invention extracts a water-soluble, neutral polysaccharide with a molecular weight between 20-22 kDa. This invention uses the Sophora japonica extract to treat renal interstitial fibrosis. Multiple studies, including cellular and animal studies, have demonstrated that the traditional Chinese medicine Sophora japonica can inhibit renal interstitial fibrosis, making it a potential drug for clinical application and bringing greater benefits to patients with kidney disease.

The present application relates to the technical field of pharmaceutical analysis, and in particular to a combined analysis method for exploring the effect of Huangkui capsules on improving chronic kidney injury of tacrolimus based on metabolomics and proteomics. The combined analysis method of the present application explores how Huangkui capsules improve the mechanism of chronic kidney injury of tacrolimus from multiple dimensions, which is beneficial to in-depth analysis of the specific effects of Huangkui capsules at the molecular, cellular and tissue levels, reveals the key path and regulation mechanism of kidney protection, and can also provide a scientific basis for optimizing clinical application, further promoting the modernization of traditional Chinese medicine and its wide application in the treatment of kidney disease.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.